Compounds > diclofenac

diclofenac and tacrolimus

diclofenac has been researched along with tacrolimus in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's4 (36.36)29.6817
2010's6 (54.55)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chang, TK; Ensom, MH; Kiang, TK1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ciccarelli, A; de Crescenzo, G; de Paulis, A; Marinò, D; Marinò, I; Marone, G1
Aebischer, P; Pralong, WF; Schneider, BL; Schwenter, F1
Kita, Y; Morikawa, N; Muramoto, M; Okitsu, O; Yamazaki, T1
Ceulemans, LJ; De Hertogh, G; Pirenne, J; Van Cromphaut, S; Vermeire, S1

Reviews

2 review(s) available for diclofenac and tacrolimus

ArticleYear
UDP-glucuronosyltransferases and clinical drug-drug interactions.
    Pharmacology & therapeutics, 2005, Volume: 106, Issue:1

    Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic

2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

9 other study(ies) available for diclofenac and tacrolimus

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs.
    Arthritis and rheumatism, 1997, Volume: 40, Issue:3

    Topics: Adenosine; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chymases; Cyclosporine; Diclofenac; Histamine Release; Humans; Immunoglobulin E; Immunosuppressive Agents; Leukotriene C4; Mast Cells; Methotrexate; Middle Aged; Polyenes; Prostaglandins D; Rheumatic Diseases; Serine Endopeptidases; Sirolimus; Substance P; Sulfonamides; Synovial Membrane; Tacrolimus; Tryptases

1997
Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2003, Volume: 7, Issue:4

    Topics: Animals; Capsules; Cell Transplantation; Cells, Cultured; Dexamethasone; Diclofenac; Erythropoietin; Female; Gene Expression; Genetic Engineering; Genetic Vectors; Graft Survival; Hematocrit; Immunosuppressive Agents; Inflammation; Mice; Mice, Inbred C3H; Myoblasts; Plasmids; Tacrolimus; Transplantation Tolerance

2003
Discovery of a novel neuroprotective compound, AS1219164, by high-throughput chemical screening of a newly identified apoptotic gene marker.
    European journal of pharmacology, 2011, Nov-01, Volume: 669, Issue:1-3

    Topics: Aniline Compounds; Apoptosis; Biomarkers; Caspase 3; Cell Line, Tumor; Cell Survival; Diclofenac; Gene Expression Profiling; Gene Expression Regulation; Genes, Reporter; High-Throughput Screening Assays; Humans; Immunosuppressive Agents; Luciferases; Neuroprotective Agents; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Pyridines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tacrolimus; Thapsigargin; Trans-Activators; Transcription Factors

2011
Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation.
    Transplantation, 2015, Volume: 99, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Diclofenac; Fatal Outcome; Female; Femoral Vein; Graft Survival; Humans; Immunosuppression Therapy; Intermittent Claudication; Intestines; Liver Failure; Liver Transplantation; Middle Aged; Popliteal Vein; Shock; Steroids; Tacrolimus; Treatment Outcome

2015